BidaskClub upgraded shares of Cytosorbents (NASDAQ:CTSO) from a hold rating to a buy rating in a research note issued to investors on Thursday, August 23rd.

Several other equities analysts have also recently commented on CTSO. HC Wainwright reaffirmed a buy rating and set a $14.00 price objective on shares of Cytosorbents in a research note on Wednesday, May 9th. Maxim Group set a $12.00 price objective on shares of Cytosorbents and gave the company a buy rating in a research note on Wednesday, May 9th. ValuEngine raised shares of Cytosorbents from a buy rating to a strong-buy rating in a research note on Saturday, May 12th. Finally, Cowen reaffirmed a buy rating and set a $15.00 price objective on shares of Cytosorbents in a research note on Friday, August 3rd. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of Buy and a consensus target price of $14.56.

Shares of CTSO traded down $0.40 during trading hours on Thursday, hitting $12.85. The company’s stock had a trading volume of 335,932 shares, compared to its average volume of 224,119. The company has a market capitalization of $422.34 million, a price-to-earnings ratio of -40.16 and a beta of 0.15. The company has a quick ratio of 8.60, a current ratio of 8.82 and a debt-to-equity ratio of 0.46. Cytosorbents has a 52-week low of $5.28 and a 52-week high of $14.95.

Cytosorbents (NASDAQ:CTSO) last posted its earnings results on Thursday, August 2nd. The medical research company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The business had revenue of $5.76 million during the quarter, compared to analysts’ expectations of $5.08 million. Cytosorbents had a negative return on equity of 100.51% and a negative net margin of 74.60%. sell-side analysts expect that Cytosorbents will post -0.56 earnings per share for the current fiscal year.

In other news, COO Vincent Capponi sold 10,435 shares of the business’s stock in a transaction that occurred on Friday, August 3rd. The shares were sold at an average price of $13.06, for a total value of $136,281.10. Following the completion of the sale, the chief operating officer now directly owns 335,603 shares in the company, valued at approximately $4,382,975.18. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Kathleen P. Bloch sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 3rd. The stock was sold at an average price of $12.54, for a total transaction of $125,400.00. Following the completion of the sale, the chief financial officer now owns 260,004 shares of the company’s stock, valued at $3,260,450.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 85,936 shares of company stock valued at $1,188,991. 6.90% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the stock. Pegasus Partners Ltd. bought a new stake in Cytosorbents during the 2nd quarter valued at $114,000. Metropolitan Life Insurance Co. NY bought a new stake in Cytosorbents during the 2nd quarter valued at $119,000. PEAK6 Investments L.P. bought a new stake in Cytosorbents during the 2nd quarter valued at $168,000. MetLife Investment Advisors LLC bought a new stake in Cytosorbents during the 2nd quarter valued at $169,000. Finally, Commonwealth Equity Services LLC bought a new stake in Cytosorbents during the 2nd quarter valued at $199,000. Institutional investors own 24.91% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.

See Also: Price to Earnings Ratio (PE)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.